Table 2.
Impact of [18F]flutemetamol PET on clinical diagnosis according to clinical diagnosis prior to PET
| Pre-PET etiology | AD (n = 144) |
FTD (n = 28) |
OD (n = 19) |
NN (n = 20) |
||||
|---|---|---|---|---|---|---|---|---|
| PET result | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative |
| n | 110 | 34 | 6 | 22 | 8 | 11 | 9 | 11 |
| Change in diagnosis | 0 (0%) | 26 (76%) | 4 (67%) | 0 (0%) | 2 (25%) | 0 (0%) | 9 (100%) | 0 (0%) |
| Changed diagnosis after PET | 12 NN 7 FTD 3 DLB 2 CBD 1 VaD 1 CTE |
4 AD | 1 DLB 1 AD |
9 AD | ||||
| Pre-PET diagnostic confidence (%) | 72 ± 11 | 68 ± 11 | 66 ± 12 | 67 ± 14 | 72 ± 14 | 70 ± 11 | 58 ± 8 | 57 ± 7 |
| Post-PET diagnostic confidence (%) | 98 ± 4 | 70 ± 16 | 84 ± 17 | 83 ± 14 | 78 ± 13 | 76 ± 14 | 96 ± 5 | 79 ± 14 |
| Δ Diagnostic confidence | 25 ± 11a | 1 ± 14 | 19 ± 18a | 16 ± 16a | 6 ± 15 | 6 ± 13 | 38 ± 10a | 22 ± 16a |
| Increase in diagnostic confidence (%) | 109 (99%) | 17 (50%) | 6 (100%) | 18 (82%) | 6 (75%) | 7 (64%) | 9 (100%) | 11 (100%) |
Data are presented as mean ± SD or n (%). Differences between pre-PET and post-PET diagnostic confidence were assessed using paired-sample t tests and presented as Δ diagnostic confidence
aIncreased diagnostic confidence after PET, P < 0.05
PET positron emission tomography, AD Alzheimer’s disease dementia, FTD frontotemporal dementia, OD other dementia diagnosis, NN non-neurodegenerative diagnosis, VaD vascular dementia DLB dementia with Lewy bodies, CBD corticobasal degeneration, CTE chronic traumatic encephalopathy